Skip to main content
Clinical Trials/CTRI/2023/03/050796
CTRI/2023/03/050796
Completed
Phase 4

â??Dermatological safety evaluation of test products by Primary Irritation Patch Test within 24 hours of apply on healthy human all skin types

Dabur India Limited0 sites24 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Not specified
Sponsor
Dabur India Limited
Enrollment
24
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
April 6, 2023
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\.Voluntary men and women ratio of 1:1 between 18 and 65 years.
  • 2\.Having healthy skin on test area as assessed by dermatological examination.
  • 3\.For whom the investigator considers that the compliance will be correct.
  • 4\.Subjects with normal, dry, oily and combination skin
  • 5\.Subjects cooperating informed of the need and duration of the examination and ready to comply
  • with protocol procedures.

Exclusion Criteria

  • 1\.Pregnant/nursing mothers.
  • 2\.Scars, excessive terminal hair, or tattoo on the studied area.
  • 3\.Dermatological infection/pathology on level of studied area.
  • 4\.Hypersensitivity, allergy antecedent (to any cosmetic product, raw material)
  • 5\.Any clinically significant systemic or cutaneous disease, which may interfere with study treatment or

Outcomes

Primary Outcomes

Not specified

Similar Trials